As autumn moves to winter, the WHO/Europe, EC and ECDC are issuing a clear, urgent message: people who remain unprotected against both COVID-19 and seasonal influenza – especially the most vulnerable and at-risk – should take up any offer for vaccination to prevent or mitigate the impact of these co-circulating respiratory infections.
This document presents the core protocol for ECDC studies of CVE and IVE against symptomatic laboratory-confirmed influenza or SARS-CoV-2 infection, respectively, at primary care level.
To improve the understanding of experienced HIV stigma in the community, ECDC initiated an exploratory survey in 2021 to measure HIV-related stigma across Europe and Central Asia.
This evidence brief summarises the progress towards UN Sustainable Development Goal 3.3 to ‘eliminate the epidemic of AIDS’ in Europe and Central Asia.
Progress towards ending the AIDS epidemic by 2030 is variable across the region, and most countries in Europe and Central Asia are currently far from achieving the 2025 targets.
Prevalence data from sources such as population surveys can be a useful complement to case based surveillance data for hepatitis C. Case-based surveillance has limitations as most diagnosed cases are chronic in nature and detection of cases depends largely on testing practices. Prevalence data can therefore contribute towards a fuller understanding of the epidemiology of hepatitis C.
Prevalence data from sources such as population surveys can be a useful complement to case based surveillance data for hepatitis B. Case-based surveillance has limitations as most diagnosed cases are chronic in nature and detection of cases depends largely on testing practices. Prevalence data can therefore contribute towards a fuller understanding of the epidemiology of hepatitis B.